Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUIGEN Chronic-Dose Study: Generic Lamotrigine Bioequivalence
NCT01713777Phase 4Completed
- Sponsor
- University of Cincinnati
- Start
- Apr 2013
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lamotrigine in epilepsy, sponsored by University of Cincinnati. Primary endpoint: Maximum Plasma Concentration at 18 months. Started Apr 2013; status: completed.
02
Drugs
lamotrigine
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT01713777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01713777.